News

Catalyst Pharma is currently conducting a number of non-clinical safety and efficacy studies with CPP-115 to support various indications and expects to file an IND with respect to

The MHRA inspection was conducted on the GMP side to determine whether Almac’s IXRS integrated phone and web response system was able to adequately ensure that expired products

Winton will report to Bart Peterson, senior vice president, Corporate Affairs and Communications. Winton is expected to take up the responsibility for Communications across Lilly, including oversight of

PASPORT-CUSHINGS (PASireotide clinical trial PORTfolio – CUSHING’S disease), a randomised study to evaluate a medical therapy in patients with Cushing’s disease, is part of a large-scale global clinical

Glatiramer acetate is an immunomodulator drug for currently used to treat multiple sclerosis. Copaxone is a random polymer of four amino acids found in myelin basic protein, namely

The patent covers the innovator’s syringe injection system, which enables users to achieve the correct angle and depth of subcutaneous and intramuscular injections. The ConfiDisc syringe injection system,

Furthermore, Innocoll agrees to grant Merus a right of first refusal for all current pipeline advanced wound care products for the Canadian Market. The three products are indicated

Net income increased $5.1m from net loss of $2.2m for the year ended 31 May 2009 to net income of approximately $2.9m for the year ended 31 May

Sun Pharma’s units have raised their equity stake in Taro to 48.7% and voting rights to 65.8%, according to reports. The acquisition is in pursuant to the option